<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00415506</url>
  </required_header>
  <id_info>
    <org_study_id>e1529</org_study_id>
    <nct_id>NCT00415506</nct_id>
  </id_info>
  <brief_title>Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation</brief_title>
  <official_title>A PhaseI/II Prospective, Randomized, Dose-Ranging Pilot Study of Rituximab in the Treatment of Refractory Scleritis and Non-Infectious Orbital Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of Rituximab in refractory&#xD;
      scleritis and non-infectious orbital inflammation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of Medications</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Reduction (decrease in dosage) of systemic corticosteroids or immunosuppressive therapy by at least 50% by 24 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improved Control of Inflammation</measure>
    <time_frame>24 weeks</time_frame>
    <description>For patients with scleritis, disease activity as measured by a modified grading system first described by McCluskey et al. (McCluskey and Wakefield 1987; McCluskey and Wakefield 1991). Improvement in scleritis activity will be defined as a reduction in this grading score of 2 or more, or an overall score of 4 or less by 24 weeks.&#xD;
For patients with orbital inflammation, disease activity as measured by a modified grading system first devised by Werner (Werner 1977). Improvement in orbital inflammation will be defined as a reduction in this grading score of 2 or more, or an overall score of 3 or less.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Scleritis</condition>
  <condition>Orbital Disease</condition>
  <arm_group>
    <arm_group_label>Scleritis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with Scleritis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orbital Inflammation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with Orbital Inflammation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Two 500 or 1000mg infusions over 2 weeks with the option of retreating after 6 months if initial improvement was seen.</description>
    <arm_group_label>Orbital Inflammation</arm_group_label>
    <arm_group_label>Scleritis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with non-infectious scleritis or idiopathic orbital inflammatory disease&#xD;
             requiring chronic immunosuppressive treatment for disease control.&#xD;
&#xD;
          -  Intolerance, failure to respond to, or inability to taper below prednisone &gt; 10mg/day&#xD;
             in addition to one systemic immunosuppressive (such as methotrexate, azathioprine,&#xD;
             mycophenolate mofetil, cyclosporine, cyclophosphamide, or chlorambucil).&#xD;
&#xD;
          -  Patients must be on a stable dosage of prednisone and at least one steroid-sparing&#xD;
             agent in the 30 days prior to screening/enrollment.&#xD;
&#xD;
          -  Active disease will be defined using physician judgment and supported by patient and&#xD;
             physician global ocular disease assessment of &gt; 5 cm on a 10cm visual analog scale&#xD;
             anchored by the words &quot;Inactive Eye Disease&quot; at 0 cm point and &quot;Extremely Active Eye&#xD;
             Disease&quot; at the 10cm point. Investigator discretion may apply in some cases.&#xD;
&#xD;
          -  Selected patients who are on biological agents such as TNF blockers etanercept,&#xD;
             infliximab and adalimumab with ongoing ocular disease are acceptable. There will be an&#xD;
             8 week washout period of etanercept and a 12 week washout period for infliximab and&#xD;
             adalimumab before patients are dosed with rituximab.&#xD;
&#xD;
          -  In patients with concomitant systemic autoimmune diseases including RA, SLE, Sjogrens,&#xD;
             Wegener's granulomatosis the systemic disease must be sufficiently stable and not life&#xD;
             threatening to allow tapering of steroids and/or immunosuppressive agents thus&#xD;
             allowing assessment of ocular effect of rituximab.&#xD;
&#xD;
          -  Adults of both genders &gt; 18 years old. There is no upper age limit as long as there&#xD;
             are no other disqualifying health conditions.&#xD;
&#xD;
          -  Have had a recent (&lt;3 months old) PPD skin test and are considered eligible according&#xD;
             to the tuberculosis (TB) screening, eligibility assessment, and prevention rules&#xD;
             defined in Appendix C.&#xD;
&#xD;
          -  Screening laboratory test results should be acceptable to the Investigator prior to&#xD;
             placing a patient on study drug.&#xD;
&#xD;
          -  Must have a chest radiograph within 3 months prior to first infusion with no evidence&#xD;
             of malignancy, infection or fibrosis.&#xD;
&#xD;
          -  Adequate renal function as indicated by normal BUN and creatinine levels.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Untreated thyroid disease&#xD;
&#xD;
          -  Organ threatening systemic disease as evidenced by rapidly progressive&#xD;
             glomerulonephritis, pulmonary hemorrhage or respiratory failure, seizures or&#xD;
             psychosis, progressive neuropathy or myopathy&#xD;
&#xD;
        General Safety &amp; Laboratory Exclusion Criteria&#xD;
&#xD;
        Patients will be excluded from the study based on the following criteria:&#xD;
&#xD;
          -  Hemoglobin: &lt; 8.5 gm/dL&#xD;
&#xD;
          -  Platelets: &lt; 100,000/mm&#xD;
&#xD;
          -  AST or ALT &gt;2.5 x Upper Limit of Normal unless related to primary disease.&#xD;
&#xD;
          -  Positive Hepatitis B or C serology (Hep B Surface antigen and Hep C antibody)&#xD;
&#xD;
          -  History of positive HIV (HIV conducted during screening if applicable)&#xD;
&#xD;
          -  Treatment with any investigational agent within 4 weeks of screening or 5 half-lives&#xD;
             of the investigational drug (whichever is longer)&#xD;
&#xD;
          -  Receipt of a live vaccine within 4 weeks prior to randomization&#xD;
&#xD;
          -  Previous Treatment with Rituximab (MabThera® / Rituxan®)&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions to humanized or murine monoclonal&#xD;
             antibodies&#xD;
&#xD;
          -  History of recurrent significant infection or history of recurrent bacterial&#xD;
             infections&#xD;
&#xD;
          -  Known active bacterial, viral, fungal, mycobacterial, or other infection (including&#xD;
             tuberculosis or atypical mycobacterial disease, but excluding fungal infections of&#xD;
             nail beds) or any major episode of infection requiring hospitalization or treatment&#xD;
             with i.v. antibiotics within 4 weeks of screening, or oral antibiotics within 2 weeks&#xD;
             prior to screening&#xD;
&#xD;
          -  Unstable steroid dose in the past 4 weeks&#xD;
&#xD;
          -  Lack of peripheral venous access&#xD;
&#xD;
          -  History of drug, alcohol, or chemical abuse within 6 months prior to screening&#xD;
&#xD;
          -  Pregnancy (a negative serum pregnancy for all women of childbearing potential at&#xD;
             screening and negative urine pregnancy test prior to each infusion) or lactation&#xD;
&#xD;
          -  Concomitant or previous malignancies, with the exception of curatively resected&#xD;
             non-melanoma skin carcinomas or carcinoma in situ of the cervix&#xD;
&#xD;
          -  History of psychiatric disorder that would interfere with normal participation in this&#xD;
             protocol&#xD;
&#xD;
          -  Significant cardiac or pulmonary disease (including obstructive pulmonary disease)&#xD;
&#xD;
          -  Any other disease, metabolic dysfunction, physical examination finding, or clinical&#xD;
             laboratory finding giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates the use of an investigational drug or that may affect the&#xD;
             interpretation of the results or render the patient at high risk from treatment&#xD;
             complications&#xD;
&#xD;
          -  Inability to comply with study and follow-up procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James T Rosenbaum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric B Suhler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>December 21, 2006</study_first_submitted>
  <study_first_submitted_qc>December 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2006</study_first_posted>
  <results_first_submitted>May 20, 2013</results_first_submitted>
  <results_first_submitted_qc>May 20, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 8, 2013</results_first_posted>
  <last_update_submitted>August 8, 2013</last_update_submitted>
  <last_update_submitted_qc>August 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Jim Rosenbaum</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleritis</mesh_term>
    <mesh_term>Orbital Diseases</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from January 2007 through March of 2010. Subjects were recruited from the investigator's medical clinic.</recruitment_details>
      <pre_assignment_details>Of the 20 subjects enrolled, two subjects had both orbital disease and scleritis. These two subjects were followed for both indications.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Scleritis</title>
          <description>Patients with non-infectious scleritis and is a phase II, randomized, double-blinded, prospective clinical trial of two different doses of rituximab to compare the safety and efficacy of these 2 doses. Patients will be randomized to either 500 mg or 1000 mg of rituximab administered intravenously two weeks apart.</description>
        </group>
        <group group_id="P2">
          <title>Orbital Inflammation</title>
          <description>Patients with non-infectious orbital inflammatory disease, and is a phase I, prospective clinical trial to examine the safety of the 2 infusions of rituximab intravenously, 2 weeks apart, in the treatment of non-infectious orbital inflammation. The first 5 patients will receive 1000 mg of rituximab at each infusion, any additional patients will be randomized to receive either 500 mg or 1000 mg of rituximab.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Scleritis</title>
          <description>Subjects with Scleritis</description>
        </group>
        <group group_id="B2">
          <title>Orbital Inflammation</title>
          <description>Subjects with Orbital Inflammation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction of Medications</title>
        <description>Reduction (decrease in dosage) of systemic corticosteroids or immunosuppressive therapy by at least 50% by 24 weeks.</description>
        <time_frame>24 Weeks</time_frame>
        <population>Only patients currently on systemic corticosteroids were analyzed for this outcome point.</population>
        <group_list>
          <group group_id="O1">
            <title>Scleritis</title>
            <description>Subjects with Scleritis</description>
          </group>
          <group group_id="O2">
            <title>Orbital Inflammation</title>
            <description>Subjects with Orbital Inflammation</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of Medications</title>
          <description>Reduction (decrease in dosage) of systemic corticosteroids or immunosuppressive therapy by at least 50% by 24 weeks.</description>
          <population>Only patients currently on systemic corticosteroids were analyzed for this outcome point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Improved Control of Inflammation</title>
        <description>For patients with scleritis, disease activity as measured by a modified grading system first described by McCluskey et al. (McCluskey and Wakefield 1987; McCluskey and Wakefield 1991). Improvement in scleritis activity will be defined as a reduction in this grading score of 2 or more, or an overall score of 4 or less by 24 weeks.&#xD;
For patients with orbital inflammation, disease activity as measured by a modified grading system first devised by Werner (Werner 1977). Improvement in orbital inflammation will be defined as a reduction in this grading score of 2 or more, or an overall score of 3 or less.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Scleritis</title>
            <description>Subjects with Scleritis</description>
          </group>
          <group group_id="O2">
            <title>Orbital Inflammation</title>
            <description>Subjects with Orbital Inflammation</description>
          </group>
        </group_list>
        <measure>
          <title>Improved Control of Inflammation</title>
          <description>For patients with scleritis, disease activity as measured by a modified grading system first described by McCluskey et al. (McCluskey and Wakefield 1987; McCluskey and Wakefield 1991). Improvement in scleritis activity will be defined as a reduction in this grading score of 2 or more, or an overall score of 4 or less by 24 weeks.&#xD;
For patients with orbital inflammation, disease activity as measured by a modified grading system first devised by Werner (Werner 1977). Improvement in orbital inflammation will be defined as a reduction in this grading score of 2 or more, or an overall score of 3 or less.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected for each subject during study participation, up to 48 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Orbital Inflammation</title>
          <description>Subjects with Orbital Inflammation</description>
        </group>
        <group group_id="E2">
          <title>Scleritis</title>
          <description>Subjects with Scleritis</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Eric B. Suhler</name_or_title>
      <organization>Oregon Health &amp; Science University</organization>
      <phone>503-494-5023</phone>
      <email>suhlere@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

